News

Ionis Completes Enrollment of REVEAL Cohort 1

July 6, 2026

Share

Ionis announced that they have completed enrollment of Cohort 1 in the Phase 3 clinical trial of ION582, REVEAL.

“Guided by input from the Angelman community, REVEAL was intentionally designed to evaluate obudanersen across a broad range of people living with Angelman syndrome, reflecting the real-world diversity of this condition. We are deeply grateful to the entire Angelman syndrome community, especially the participants and their families, whose partnership made this achievement possible.” – Holly Kordasiewicz, Ph.D., executive vice president, chief development officer, Ionis. 

Individuals enrolled in REVEAL are assigned to study “Cohorts” based on their age. 

  • Individuals aged 2 – <18 years old are assigned to Cohort 1
  • Individuals aged 18 – ≤50 years old are assigned to Cohort 2. 

While enrollment in Cohort 1 has been completed, participating sites continue to screen participants for Cohort 2.

More Information

Read the Community Letter

Read the Press Release

Learn more about REVEAL 

Your donation Lifts Up the Angelman community.